The KIDCARE Study: Exploring Treatment Strategies for Rare Pediatric Illness
About Us
- 2023 Annual Meeting
- About PCORI
- The PCORI Strategic Plan
- Governance
- Evaluating Our Work
- PCORI's Advisory Panels
- Procurement Opportunities
-
Provide Input
- Proposed New Methodology Standards for Usual Care as a Comparator (2023)
-
Past Opportunities to Provide Input
- Stakeholder Views on Components of 'Patient-Centered Value' in Health and Health Care (2023)
- PCORI's Proposed Research Agenda (2021-2022)
- Proposed National Priorities for Health (2021)
- Proposed Principles for the Consideration of the Full Range of Outcomes Data in PCORI-Funded Research (2020)
- Proposed New PCORI Methodology Standards (2018)
- Data Access and Data Sharing Policy: Public Comment (2017)
- Proposed New PCORI Methodology Standards (2017)
-
Comment on the Proposed New and Revised PCORI Methodology Standards (2016)
- 1. Standards for Formulating Research Questions
- 10: Standards for Studies of Diagnostic Tests
- 12. Standards on Research Designs Using Clusters
- 13: General Comments on the Proposed Revisions to the PCORI Methodology Standards
- 2: Standards Associated with Patient-Centeredness
- 3: Standards for Data Integrity and Rigorous Analysis
- 4: Standards for Preventing and Handling Missing Data
- 5: Standards for Heterogeneity of Treatment Effects
- 6: Standards for Data Registries
- 7: Standards for Data Networks as Research-Facilitating Structures
- 8. Standards for Causal Inference Methods
- 9. Standards for Adaptive Trial Designs
- Peer-Review Process Comments (2014)
- Draft Methodology Report Public Comment Period (2012)
- Leadership
Image
Kawasaki disease is a rare form of cardiovascular disease that mainly affects children. The condition causes widespread inflammation and can lead to focal swelling, or aneurysm formation, of the arteries. Inflammatory changes of the coronary arteries, the blood vessels that supply the heart, can be life-threatening.
Children who received infliximab had shorter hospital stays and experienced fewer side effects than those given a second dose of IVIG.
The cause of Kawasaki disease is unknown, but treatment with intravenous immunoglobulin (IVIG), a potent anti-inflammatory therapy, helps most children recover. Unfortunately, up to 20 percent of children diagnosed with Kawasaki disease experience persistent symptoms that do not respond to this treatment. There are currently no clear guidelines to help direct therapy for children with resistant disease.
The KIDCARE Study, a PCORI-funded trial, recently compared treatment strategies for resistant Kawasaki disease. The research team assessed the effectiveness of a medicine called infliximab compared to giving a second dose of IVIG. More than 100 children who had resistant disease and received care at 30 health centers across the United States were evaluated. The team found that children who received infliximab had shorter hospital stays and experienced fewer side effects, including anemia, than those given a second dose of IVIG. This is one of few trials to evaluate therapies for a rare group of patients experiencing the already rare condition of Kawasaki disease.
These study findings were published in The Lancet Child & Adolescent Health.
Tags
Recent Posts
What's Happening at PCORI?
The Patient-Centered Outcomes Research Institute sends weekly emails about opportunities to apply for funding, newly funded research studies and engagement projects, results of our funded research, webinars, and other new information posted on our site.
Image
